Showing 4491-4500 of 9914 results for "".
- Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Precisely to the Skinhttps://practicaldermatology.com/news/take-that-acne-bpx-01-topical-gel-delivers-minocycline-precisely-to-the-skin/2458490/BioPharmX Corporation’s novel topical minocycline, BPX-01, may be as effective as its oral counterpart minus the systemic side effects, new research suggests. "These results are promising, that topical minocycline gel delivered as BP
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- CeraVe: Suncare Products Get Skin Cancer Foundation Seal of Recommendationhttps://practicaldermatology.com/news/cerave-suncare-products-get-skin-cancer-foundation-seal-of-recommendation/2458495/Two products from Valeant Consumer Healthcare's CeraVe skincare line have received The Skin Cancer Foundation (SCF) Seal of Recommendation for sunscreens. CeraVe® AM Facial Moisturizing Lotion with SPF 30 has earned the “Daily Use” Seal and CeraVe
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- FDA Clears Syneron Candela's UltraShape Power for Fat Destructionhttps://practicaldermatology.com/news/fda-clears-syneron-candelas-ultrashape-power-for-fat-destruction/2458499/The FDA cleared Syneron Medical Ltd.'s non-invasive fat destruction device, UltraShape Power. for non-invasive reduction of abdominal circumference via fat cell destruction. UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat, offering measurab
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),
- Preston Romm Joins Suneva Medical As Chief Operating Officerhttps://practicaldermatology.com/news/preston-romm-joins-suneva-medical-as-chief-operating-officer/2458528/Suneva Medical Inc. appointed Preston Romm to chief operating officer (COO). Romm joins Suneva Medical with more than 30 years of experience and will be responsible for leading the company's sales, marketing and operations. Previously serving as president of Oba
- Dermatologist Swaps His Scalpel for a Penhttps://practicaldermatology.com/news/dermatologist-swaps-his-scalpel-for-a-pen/2458535/Steven M. Hacker, MD, a Delray Beach dermatologist and author, has released his debut novel. "The Caduceus and The Swastika". The thriller tells a frightening but endearing story of what happened to a group of medical students when Nazi's became medical professors and began a
- Solta Medical Launches Consumer Campaign to Empower LGBTQ Communityhttps://practicaldermatology.com/news/solta-medical-launches-consumer-campaign-to-empower-lgbtq-community/2458538/Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s true self. In addition, Solta Medical was the exclusive medical aesthetic category sponsor of the
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ